ATRC:NSD-AtriCure Inc. (USD)

EQUITY | Medical Instruments & Supplies | NASDAQ Global Market

Last Closing

USD 23.17

Change

0.00 (0.00)%

Market Cap

USD 0.64B

Volume

0.38M

Analyst Target

USD 55.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AtriCure Inc is a medical device company. It develops, manufactures and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

-5.82 (-1.51%)

USD 133.13B
COO The Cooper Companies Inc.

-1.93 (-2.04%)

USD 18.82B
HOLX Hologic Inc

+0.43 (+0.57%)

USD 17.83B
RGEN Repligen Corporation

-3.47 (-2.08%)

USD 9.30B
XRAY Dentsply Sirona Inc

+0.29 (+1.04%)

USD 6.35B
MMSI Merit Medical Systems Inc

N/A

USD 4.28B
AZTA Azenta Inc

-0.26 (-0.50%)

USD 2.78B
ICUI ICU Medical Inc

+1.27 (+1.19%)

USD 2.31B
STAA STAAR Surgical Company

+1.22 (+2.88%)

USD 2.31B
LMAT LeMaitre Vascular Inc

+0.08 (+0.11%)

USD 1.47B

ETFs Containing ATRC

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -35.08% 28% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.08% 28% F 15% F
Trailing 12 Months  
Capital Gain -47.33% 25% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.33% 25% F 20% F
Trailing 5 Years  
Capital Gain -22.66% 54% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.66% 54% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain 16.06% 68% D+ 76% C+
Dividend Return 16.06% 68% D+ 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.41% 48% F 35% F
Risk Adjusted Return 33.87% 75% C 69% C-
Market Capitalization 0.64B 76% C+ 74% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 34.48 61% 28%
Price/Book Ratio 2.50 51% 39%
Price / Cash Flow Ratio 253.35 7% 1%
Price/Free Cash Flow Ratio -135.97 98% 98%
Management Effectiveness  
Return on Equity -6.60% 58% 52%
Return on Invested Capital -6.04% 56% 43%
Return on Assets -3.24% 55% 44%
Debt to Equity Ratio 13.00% 65% 68%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector